Document is current
Any future updates will be listed below
-
Authors
Castagnoli, Lorenzo
Bonì, Francesco
Bigliardi, Martina
Toneguzzo, Paolo
Corsetto, Paola A.
Galasso, Giorgia
Franceschini, Alma
Cocomazzi, Paolo
Regondi, Viola
Capuzzoni, Cristian
Rizzo, Angela M.
Ligorio, Francesca
Vernieri, Claudio
Seneci, Pierfausto
Arosio, Daniela
Tagliabue, Elda
Mastrangelo, Eloise
Milani, Mario
Pupa, Serenella M.
-
Funding
Funding for this research was provided by:
Fondazione Umberto Veronesi (Call 2023)
Fondazione Pezcoller (Call 2022)
Fondazione AIRC per la ricerca sul cancro ETS (Id#22943, Id#22943, Id#22943, Id#22943, Id#22943)
Italian Consortium “Cineca” (IsCa7_drp 2023-2024)
- License Information
-
More Information
Article History
Received: 17 January 2025
Accepted: 1 August 2025
First Online: 6 August 2025
Declarations
:
: C. Vernieri reports research grants from Roche (to the Institution); Role in Advisory Boards or consultancies: Eli Lilly; Novartis; Pfizer; Daiichi Sankyo; Menarini Stemline; Astra Zeneca. Honoraria as a speaker: Eli Lilly; Novartis; MSD; Pfizer, Istituto Gentili; Menarini Stemline; Accademia Nazionale di Medicina; F. Ligorio reports Honoraria as a speaker from Novartis, Pfizer, Eli-Lilly, Accademia di Medicina. No competing interests were declared by the other authors.
